22 June 2018 - - The Oakland, California-based stem cell research-focused California Institute for Regenerative Medicine (CIRM) has featured Tokyo, Japan-based regenerative medical products company SanBio Group's (TOKYO: 4592) US-based phase 1/2a clinical trial of SB623 for the treatment of chronic motor deficit from ischemic stroke during a CIRM Facebook event, the company said.
The presentation is available for viewing through the CIRM website.
SanBio is conducting a phase 2b clinical trial of SB623 for the treatment of chronic motor deficit from ischemic stroke in the US together with its development partner in the US and Canada, Sumitomo Dainippon Pharma Co., Ltd.
On its own, SanBio is conducting a global phase 2 clinical trial of SB623 targeting chronic motor deficit from traumatic brain injury in Japan and the US.
SanBio is headquartered in Tokyo with its main research and development base in Mountain View, California. The company has cell-based products in various stages of research, development, and clinical trials.
CIRM funds stem cell research and partners with its grantees to support their efforts to move novel ideas into treatments to test in the clinic.
Some therapies discovered through stem cell research involve transplanting the cells themselves, others will be drugs discovered through modeling diseases in a petri dish, while still others will be diagnostics that allow doctors to diagnose and treat diseases more effectively.
CIRM funding promotes all areas of stem cell research that show promise to accelerating treatments to patients in need.